GlassScriptPhysician profile
Ashok Yanamadala
NPI 1558418301
$3,290.85
in general payments reported to CMS, 2019-2025
21 companies · $14.51 in 2025
The $14.51 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $301 · 2021: $579 · 2022: $1,429 · 2023: $148 · 2025: $14.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $570.26 | 2019-2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sunovion Pharmaceuticals INC. | $514.69 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $449.29 | 2021-2023 | |
| Abbvie INC. | $363.88 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $247.36 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $236.00 | 2019-2022 | |
| Lundbeck LLC | $181.67 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $168.29 | 2019-2022 | |
| Alkermes, INC. | $157.06 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $109.97 | 2019-2022 | |
| Allergan, INC. | $51.85 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.26 | 2019 | |
| Indivior INC. | $33.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $31.08 | 2019-2020 | |
| Adlon Therapeutics L.P. | $30.56 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.95 | 2022 | |
| Neurocrine Biosciences, INC. | $17.97 | 2022 | |
| Merck Sharp & Dohme LLC | $15.79 | 2022 | |
| Bausch Health US, LLC | $14.75 | 2022 | |
| Almatica Pharma LLC | $14.51 | 2025 | Loreev Xr |
| Noven Therapeutics, LLC | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Yanamadala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.